NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT01996748,Clinical Study to Assess the Efficacy and Safety of DF277 Compared to Placebo in the Treatment of Otic Eczema,https://clinicaltrials.gov/study/NCT01996748,,COMPLETED,The purpose of this study is to evaluate the safety and efficacy of DF277 for the treatment of otic eczema.,YES,Otic Eczema,DRUG: DF277|DRUG: Placebo,"Analysis of the Itching Change at the End of Treatment., The analysis of the itching change at the end of treatment (mean itching on days 4-8 compared to baseline). Itching was assessed on a 4 point ordinal scale; 0=absent, 1=mild, 2=moderate, 3=severe, Baseline and days 4-8","Change in Signs/ Symptoms, - Change in itching at follow-up (mean itching on days 9-15 compared to baseline)., Baseline and days 9-15|Change in Mean Global Scores of Otoscopic Signs (Erythema, Edema and Scaling) at the End of Treatment (Day 8) Compared to Baseline (Day 1)., Analysis of the change on global scores of otoscopic signs at the end of treatment (mean global scores of otoscopic signs on day 8 compared to baseline).

Erythema, edema and scaling were assessed on a 4 point ordinal scale; 0=absent, 1=mild, 2=moderate, 3=severe., Baseline and day 8|Change in Mean Global Scores of Otoscopic Signs (Erythema, Edema and Scaling) at the End of Follow-up (Day 15) Compared to Baseline (Day 1)., Analysis of the change on global scores of otoscopic signs at the end of treatment (mean global scores of otoscopic signs on day 15 compared to baseline).

Erythema, edema and scaling were assessed on a 4 point ordinal scale; 0=absent, 1=mild, 2=moderate, 3=severe., Baseline and day 15",,Salvat,,ALL,"CHILD, ADULT, OLDER_ADULT",PHASE3,135,INDUSTRY,INTERVENTIONAL,"Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT",DF277OTIII/11ES01,2012-02,2012-03,2013-03,2013-11-27,2016-12-21,2017-05-30,"Laboratorios SALVAT, S.A., Esplugues de Llobregat, Barcelone, 08950, Spain",
